Validation, demonstration, and promotion of the “Three Technical Innovations Plus Health System Strengthening” comprehensive tuberculosis prevention and control model: the China National Health Commission-Bill and Melinda Gates Foundation Tuberculosis Project

doi:10.3969/j.issn.1000-6621.2021.08.001

Abstract

Abstract:

So far, tuberculosis has still been a major infectious disease that seriously endangers human health. Particularly, the global pandemic of the Corona Virus Disease 2019 has brought new challenges to global tuberculosis prevention and control. This article reviews the 10-year history of the China National Health Commission-Bill and Melinda Gates Foundation Tuberculosis Project based on the validation, demonstration and promotion of the “Three Technical Innovations Plus Health System Strengthening” comprehensive tuberculosis prevention and control model, to provide a reference for strengthening the prevention and control of tuberculosis in China and the world.

Key words: Tuberculosis, Universal precautions, Health services research, Consensus development conference

ZHANG Hui, CHENG Jun, QU Yan, HUANG Fei, WANG Ni, HUAN Shi-tong. Validation, demonstration, and promotion of the “Three Technical Innovations Plus Health System Strengthening” comprehensive tuberculosis prevention and control model: the China National Health Commission-Bill and Melinda Gates Foundation Tuberculosis Project[J]. Chinese Journal of Antituberculosis, 2021, 43(8): 757-760. doi: 10.3969/j.issn.1000-6621.2021.08.001

References 28

[1]	Xia H, Song YY, Zhao B, et al. Multicentre evaluation of Ziehl-Neelsen and light-emitting diode fluorescence microscopy in China. Int J Tuberc Lung Dis, 2013, 17(1):107-112. doi: 10.5588/ijtld.12.0184. doi: 10.5588/ijtld.12.0184 URL
[2]	欧喜超, 夏辉, 李强, 等. 快速核酸提取环介导等温扩增检测技术在肺结核诊断中的应用评价. 中国防痨杂志, 2016, 38(5):393-397. doi: 10.3969/j.issn.1000-6621.2016.05.014.
[3]	欧喜超, 夏辉, 李强, 等. 快速DNA提取环介导等温扩增技术检测结核分枝杆菌的成本分析. 中国防痨杂志, 2014, 36(7):596-599. doi: 10.3969/j.issn.1000-6621.2014.07.017.
[4]	Ou X, Li Q, Xia H, et al. Diagnostic accuracy of the PURE-LAMP test for pulmonary tuberculosis at the county-level laboratory in China. PLoS One, 2014, 9(5):e94544. doi: 10.1371/journal.pone.0094544. doi: 10.1371/journal.pone.0094544 URL
[5]	欧喜超, 夏辉, 李强, 等. 结核分枝杆菌及利福平耐药核酸扩增检测成本分析. 中国防痨杂志, 2013, 35(9):723-728.
[6]	赵冰, 欧喜超, 夏辉, 等. Xpert Mtb/RIF检测技术在结核病诊断中的应用评价. 中国防痨杂志, 2014, 36(6):462-466. doi: 10.3969/j.issn.1000-6621.2014.06.011.
[7]	Ou X, Xia H, Li Q, et al. A feasibility study of the Xpert MTB/RIF test at the peripheral level laboratory in China. Int J Infect Dis, 2015, 31:41-46. doi: 10.1016/j.ijid.2014.09.011. doi: 10.1016/j.ijid.2014.09.011 URL
[8]	Li Q, Dong HY, Pang Y, et al. Multicenter evaluation of the molecular line probe assay for multidrug resistant Mycobacterium tuberculosis detection in China. Biomed Environ Sci, 2015, 28(6):464-467. doi: 10.3967/bes2015.066.
[9]	Pang Y, Xia H, Zhang Z, et al. Multicenter evaluation of genechip for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol, 2013, 51(6):1707-1713. doi: 10.1128/JCM.03436-12. doi: 10.1128/JCM.03436-12 URL pmid: 23515537
[10]	Pang Y, Li Q, Ou X, et al. Cost-effectiveness comparison of Genechip and conventional drug susceptibility test for detecting multidrug-resistant tuberculosis in China. PLoS One, 2013, 8(7):e69267. doi: 10.1371/journal.pone.0069267. doi: 10.1371/journal.pone.0069267 URL
[11]	Liu X, Lewis JJ, Zhang H, et al. Effectiveness of Electronic Reminders to Improve Medication Adherence in Tuberculosis Patients: A Cluster-Randomised Trial. PLoS Med, 2015, 12(9):e1001876. doi: 10.1371/journal.pmed.1001876. doi: 10.1371/journal.pmed.1001876 URL
[12]	王倪, 周林, 池俊英, 等. 不同服药方式抗结核固定剂量复合剂的疗效与不良反应分析. 现代预防医学, 2012, 39(23):6275-6277.
[13]	Li R, Ruan Y, Sun Q, et al. Effect of a comprehensive programme to provide universal access to care for sputum-smear-positive multidrug-resistant tuberculosis in China: a before-and-after study. Lancet Glob Health, 2015, 3(4):e217-e228. doi: 10.1016/S2214-109X(15)70021-5. doi: 10.1016/S2214-109X(15)70021-5 URL
[14]	Huang F, van den Hof S, Qu Y, et al. Added value of comprehensive program to provide universal access to care for sputum smear-negative drug-resistant tuberculosis, China. Emerg Infect Dis, 2019, 25(7):1289-1296. doi: 10.3201/eid2507.181417. doi: 10.3201/eid2507.181417 URL pmid: 31211666
[15]	Dong D, Jiang WX, Long Q, et al. Impact of an innovative tuberculosis financing and payment model on health service utilization by tuberculosis patients in China: do the poor fare better than the rich? Infect Dis Poverty, 2019, 8(1):44. doi: 10.1186/s40249-019-0559-z. doi: 10.1186/s40249-019-0559-z URL pmid: 31182164
[16]	Jiang WX, Long Q, Lucas H, et al. Impact of an innovative financing and payment model on tuberculosis patients’ financial burden: is tuberculosis care more affordable for the poor? Infect Dis Poverty, 2019, 8(1):21. doi: 10.1186/s40249-019-0532-x. doi: 10.1186/s40249-019-0532-x URL
[17]	周宇辉, 刘剑君. 创新结核病控制——中盖结核病项目三期典型实践. 北京: 人民卫生出版社, 2019.
[18]	Chin DP. The COVID-19 Pandemic and Elimination of Tuberculosis in China. China CDC Weekly, 2021, 3(12):260-264. doi: 10.46234/ccdcw2021.069. doi: 10.46234/ccdcw2021.069 URL
[19]	Li ZP, Mao WH, Huang F, et al. Access to quality diagnosis and rational treatment for tuberculosis: real-world evidence from China-Gates Tuberculosis Control Project Phase Ⅲ. Infect Dis Poverty, 2021, 10(1):92. doi: 10.1186/s40249-021-00875-8. doi: 10.1186/s40249-021-00875-8 URL
[20]	Jiang WX, Li ZP, Zhao Q, et al. Impacts of a comprehensive tuberculosis control model on the quality of clinical services and the financial burden of treatment for patients with drug-resistant tuberculosis in China: a mixed-methods evaluation. Infect Dis Poverty, 2021, 10(1):54. doi: 10.1186/s40249-021-00832-5. doi: 10.1186/s40249-021-00832-5 URL
[21]	王倪, 张慧, 张铁娟, 等. 使用电子药盒辅助肺结核患者服药管理的实施情况分析. 中国防痨杂志, 2020, 42(7):682-686. doi: 10.3969/j.issn.1000-6621.2020.07.008.
[22]	Wang N, Guo L, Shewade HD, et al. Effect of using electronic medication monitors on tuberculosis treatment outcomes in China: a longitudinal ecological study. Infect Dis Poverty, 2021, 10(1):29. doi: 10.1186/s40249-021-00818-3. doi: 10.1186/s40249-021-00818-3 URL
[23]	Huang F, Wang N, Li Y, et al. Multichannel Financing Reduces Economic Burden and Improves the Medical Security Level for Tuberculosis Patients. China CDC Weekly, 2020, 2(12):194-197. doi: 10.46234/ccdcw2020.051. doi: 10.46234/ccdcw2020.051 URL
[24]	Long Q, Jiang WX, Zhang H, et al. Multi-source financing for tuberculosis treatment in China: key issues and challenges. Infect Dis Poverty, 2021, 10(1):17. doi: 10.1186/s40249-021-00809-4. doi: 10.1186/s40249-021-00809-4 URL
[25]	Hu XY, Gao GY. Evaluation of the effect of the capitation compensation mechanism among pulmonary tuberculosis patients with a full period of treatment. Infect Dis Poverty, 2021, 10(1):78. doi: 10.1186/s40249-021-00861-0. doi: 10.1186/s40249-021-00861-0 URL
[26]	杜昕, 李涛, 李游, 等. 基于《全民健康保障工程建设规划》的新型《结核病监测信息系统》开发及验证. 中国防痨杂志, 2020, 42(7):662-666. doi: 10.3969/j.issn.1000-6621.2020.07.004.
[27]	Jiang WX, Huang F, Tang SL, et al. Implementing a new tuberculosis surveillance system in Zhejiang, Jilin and Ningxia: improvements, challenges and implications for China’s National Health Information System. Infect Dis Poverty, 2021, 10(1):22. doi: 10.1186/s40249-021-00811-w. doi: 10.1186/s40249-021-00811-w URL
[28]	王黎霞. 结核病防治可持续发展之路——回顾“十三五”展望“十四五”. 中国防痨杂志, 2021, 43(1):3-5. doi: 10.3969/j.issn.1000-6621.2021.01.002.